These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34794819)

  • 1. Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
    Ivanova-Markova Y; González-Domínguez A; Hidalgo A; Sánchez R; García-Agua N; García-Ruiz AJ; Amanda Vallejo-Aparicio L; García A; Rodriguez R; de Gomensoro E; Gonzalez-Inchausti MDC; Shen J; Begum N; Tafalla M
    Vaccine; 2021 Dec; 39(52):7646-7654. PubMed ID: 34794819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
    Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
    Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quality-adjusted life-years loss due to serogroup B invasive meningococcal disease in Spain.
    García A; Vallejo-Aparicio LA; Begum N; Nikitas G; González-Inchausti C; de Gomensoro E
    Vaccine; 2024 Sep; 42(22):126155. PubMed ID: 39146857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
    Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ
    Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam.
    The Nguyen PN; Hung NT; Mathur G; Pinto TJP; Minh NHL
    Hum Vaccin Immunother; 2023 Dec; 19(1):2172922. PubMed ID: 36951161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Gruhn S; Witte J; Greiner W; Damm O; Dietzsch M; Kramer R; Knuf M
    Vaccine; 2022 Mar; 40(13):1932-1947. PubMed ID: 35227520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of the Epidemiology of Invasive Meningococcal Disease and Vaccination Strategies in North Africa.
    Taha MK; Presa J; Serra L
    Int J Infect Dis; 2021 Mar; 104():189-197. PubMed ID: 33227521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017.
    Ceyhan M; Ozsurekci Y; Lucidarme J; Borrow R;
    Vaccine; 2020 Apr; 38(19):3545-3552. PubMed ID: 32199701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequelae at Hospital Discharge in 61 Children With Invasive Meningococcal Disease, Chile, 2009-2019.
    Arteta-Acosta C; Villena Martínez R; Santolaya de Pablo ME
    Pediatr Infect Dis J; 2022 Aug; 41(8):607-613. PubMed ID: 35421054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines.
    Stein-Zamir C; Shoob H; Abramson N; Block C; Keller N; Jaffe J; Valinsky L
    Hum Vaccin Immunother; 2019; 15(1):242-248. PubMed ID: 30156954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 17. Invasive meningococcal disease in the Veneto region of Italy: a capture-recapture analysis for assessing the effectiveness of an integrated surveillance system.
    Baldovin T; Lazzari R; Cocchio S; Furlan P; Bertoncello C; Saia M; Russo F; Baldo V
    BMJ Open; 2017 May; 7(4):e012478. PubMed ID: 28465304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.